Notable Guests
MS
Monika Swietlicka
3x
RJ
Rita Johnson-Greene
2x
BG
Bambi Grilley
2x
PM
Peter Marks
2x
ZR
Zachary Roberts
2x
RA
Robert Ang
2x
MF
Miguel Forte
2x
BL
Bruce Levine
2x
PT
Panteli Theocharous
2x
AZ
Alicia Zhou
1x
AS
Andrew Scharenberg
1x
AR
Andy Ramelmeier
1x
AS
Andy Stober
1x
AA
Andrew Anzalone
1x
Recent Episodes
✨
Sernova and Seraxis merge to form BetaNova, aiming for a functional cure for T1D.
Jonathan Rigby
Will Rust, Ph.D
✨
EA Weeks discusses crucial CGT deal terms like IP, manufacturing, and data rights.
EA Weeks, J.D., Ph.D
✨
Sylke Poehling explains Roche's approach: starting drug development with disease biology.
Sylke Poehling, Ph.D
✨
Dr. Panteli Theocharous discusses the rapid rise of autoimmune CAR T therapies.
Panteli Theocharous
✨
Dr. Sonal Gupta explains CoRegen's engineered Treg approach for solid tumors.
Sonal Gupta, MD, PhD
✨
Shannon Boye details Atsena Therapeutics' gene therapy strategy for Stargardt disease.
Shannon Boye, Ph.D
How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad
✨
Dr. Oren Gilad discusses precision oncology and synthetic lethality at Aprea Therapeutics.
Oren Gilad
✨
Jay Hartenbach explores Diakonos Oncology's dendritic cell therapy for solid tumors.
Jay Hartenbach
✨
Life Science Connect editors discuss the 2026 pharmaceutical and biotech landscape.
✨
Dr. Mike Ehlers discusses Ascidian Therapeutics' RNA exon editing for genetic diseases.
Mike Ehlers
✨
Gopi Shanker explains Beam Therapeutics' advancements in in vivo gene editing.
Gopi Shanker, Ph.D
✨
Dr. Naji Gehchan discusses Kyverna Therapeutics' CAR T for autoimmune diseases.
Naji Gehchan
✨
Cassie Gorsuch discusses Precision Biosciences' Arcus platform for in vivo gene editing.
Cassie Gorsuch, Ph.D
✨
Dr. Zachary Roberts discusses evolving allogeneic CAR-T for earlier intervention.
Zachary Roberts
✨
Tatyana Matveeva discusses building integrated cGMP systems for autologous cell therapies.
Tatyana Matveeva, Ph.D
✨
Carlos Buesa explains Oryzon's LSD1 inhibition strategy for various diseases.
Carlos Buesa, Ph.D
✨
Dr. Catriona Jamieson advocates for shifting focus to rare disease detection.
✨
Monika Swietlicka discusses FDA's increased regulatory flexibility in CGT development.
Monika Swietlicka
✨
Dr. Edward Kaye discusses Aurora Therapeutics' strategy for scaling CRISPR gene editing.
✨
Dr. Panteli Theocharous identifies friction points in cell therapy clinical trials.
Panteli Theocharous